Table 5.
Secondary outcome measures after 24 weeks of treatment: mean differences (s.d.) between end of treatment and baselinea
| Consultation-type allocation | Consultation |
No consultation |
|||
|---|---|---|---|---|---|
| Medication-type allocation | Individual | Complex | Placebo | Complex | Placebo |
| Group number | 1 | 2 | 3 | 4 | 5 |
| Rheumatological measuresb | |||||
| DAS-28 | |||||
| Mean (s.d.) | −0.92 (1.56) | −0.74 (0.78) | −0.98 (1.28) | −0.02 (0.92) | −0.30 (0.77) |
| n | 12 | 9 | 12 | 9 | 11 |
| Swollen joint count | |||||
| Mean (s.d.) | −2.83 (4.59) | −2.44 (2.74) | −4.00 (6.51) | 1.89 (6.98) | −1.45 (2.66) |
| n | 12 | 9 | 12 | 9 | 11 |
| Tender joint count | |||||
| Mean (s.d.) | −4.00 (8.10) | −1.22 (2.99) | −2.83 (5.56) | −1.00 (3.67) | −0.73 (3.77) |
| n | 12 | 9 | 12 | 9 | 11 |
| Current pain (VAS) | |||||
| Mean (s.d.) | −3.75 (18.83) | −15.56 (27.36) | −8.00 (27.15) | 2.33 (19.07) | −7.40 (30.72) |
| n | 12 | 9 | 11 | 9 | 10 |
| CRP, mg/l | |||||
| Mean (s.d.) | −4.50 (27.67) | −3.31 (9.29) | 2.18 (13.74) | −4.10 (8.98) | −1.54 (6.53) |
| n | 11 | 9 | 12 | 8 | 11 |
| ESR, mm/h | |||||
| Mean (s.d.) | −0.36 (6.27) | −3.00 (11.55) | 0.73 (18.70) | −4.87 (4.94) | −3.00 (7.62) |
| n | 11 | 9 | 11 | 8 | 10 |
| HAQ | |||||
| Mean (s.d.) | −0.24 (0.69) | −0.19 (0.35) | −0.24 (0.50) | −0.26 (0.43) | −0.06 (0.16) |
| n | 12 | 9 | 12 | 10 | 11 |
| Patient GA | |||||
| Mean (s.d.) | −14.50 (17.96) | −18.22 (28.49) | −13.31 (26.28) | −4.11 (24.55) | −22.36 (28.82) |
| n | 12 | 9 | 13 | 9 | 11 |
| Physician GA | |||||
| Mean (s.d.) | −9.75 (14.99) | −20.00 (19.16) | −12.92 (20.38) | −3.78 (34.98) | −7.36 (26.84) |
| n | 12 | 9 | 13 | 9 | 11 |
| Other measuresb | |||||
| Positive mood | |||||
| Mean (s.d.) | 5.58 (6.49) | 3.33 (11.20) | 2.33 (8.55) | −1.50 (6.06) | −0.45 (5.73) |
| n | 12 | 9 | 12 | 10 | 11 |
| Negative moodb | |||||
| Mean (s.d.) | −4.25 (5.96) | −2.78 (2.68) | −5.75 (9.35) | 1.88 (2.23) | −3.00 (2.76) |
| n | 12 | 9 | 12 | 10 | 11 |
| MYMOP | |||||
| Mean (s.d.) | −0.96 (0.95) | −1.00 (0.86) | −1.55 (1.37) | −0.62 (1.29) | −1.07 (0.90) |
| n | 10 | 9 | 12 | 9 | 9 |
| Number of patients who achieved 15% MYMOP, n (%) | 8 (50.0) | 7 (50.0) | 10 (62.5) | 5 (33.3) | 7 (43.8) |
| Weekly pain scores (VAS) | |||||
| Mean (s.d.) | −5.67 (19.85) | −11.2 (27.06) | −5.80 (23.42) | 0.57 (9.96) | 11.16 (29.06) |
| n | 9 | 5 | 10 | 7 | 6 |
| Weekly GA | − | ||||
| Mean (s.d.) | −6.00 (14.98) | 8.60 (21.42) | −8.2 (28.41) | −2.14 (10.54) | −16.29 (24.55) |
| n | 9 | 5 | 10 | 7 | 7 |
aThe data reported are for completed patients only. bA negative sign indicates improvement except for the positive mood construct of the PANAS, where a positive sign indicates improvement. The negative mood construct of the PANAS was adjusted accordingly so that a negative sign indicates improvement.